PE20170257A1 - Proteinas de fusion uti - Google Patents

Proteinas de fusion uti

Info

Publication number
PE20170257A1
PE20170257A1 PE2016001522A PE2016001522A PE20170257A1 PE 20170257 A1 PE20170257 A1 PE 20170257A1 PE 2016001522 A PE2016001522 A PE 2016001522A PE 2016001522 A PE2016001522 A PE 2016001522A PE 20170257 A1 PE20170257 A1 PE 20170257A1
Authority
PE
Peru
Prior art keywords
fusion proteins
uti fusion
uti
fusion
polypeptide
Prior art date
Application number
PE2016001522A
Other languages
English (en)
Inventor
Aaron Chamberlain
Mathias Schmidt
Qiang Liu
Original Assignee
Takeda Pharmaceuticals Co
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Takeda Gmbh filed Critical Takeda Pharmaceuticals Co
Publication of PE20170257A1 publication Critical patent/PE20170257A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion provee proteinas de fusion del inhibidor de tripsina urinaria (UTI), donde el companero de fusion es un polipeptido Fc. Se refiere tambien a composiciones farmaceuticas. Dicha proteina de fusion es util en el tratamiento de cancer y SIDA
PE2016001522A 2014-02-24 2015-02-23 Proteinas de fusion uti PE20170257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24

Publications (1)

Publication Number Publication Date
PE20170257A1 true PE20170257A1 (es) 2017-03-30

Family

ID=52629709

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001522A PE20170257A1 (es) 2014-02-24 2015-02-23 Proteinas de fusion uti

Country Status (37)

Country Link
US (4) US9856310B2 (es)
EP (2) EP3110434B1 (es)
JP (4) JP6574431B2 (es)
KR (2) KR102461210B1 (es)
CN (2) CN106232135B (es)
AR (1) AR101597A1 (es)
AU (4) AU2015218704B2 (es)
BR (1) BR112016019390B1 (es)
CA (2) CA2939639C (es)
CL (1) CL2016002136A1 (es)
CR (1) CR20160444A (es)
CY (1) CY1120997T1 (es)
DK (1) DK3110434T3 (es)
DO (1) DOP2016000202A (es)
EA (2) EA037256B1 (es)
EC (1) ECSP16076535A (es)
ES (1) ES2700149T3 (es)
GE (1) GEP20196970B (es)
HR (1) HRP20182029T1 (es)
IL (1) IL247321B (es)
JO (1) JO3729B1 (es)
LT (1) LT3110434T (es)
MA (1) MA39347B2 (es)
MX (2) MX2016010950A (es)
MY (1) MY178774A (es)
NZ (3) NZ760008A (es)
PE (1) PE20170257A1 (es)
PH (1) PH12016501629A1 (es)
PL (1) PL3110434T3 (es)
PT (1) PT3110434T (es)
RS (1) RS58285B1 (es)
SG (2) SG11201606691QA (es)
SI (1) SI3110434T1 (es)
TW (1) TWI694084B (es)
UA (1) UA118866C2 (es)
WO (1) WO2015127391A1 (es)
ZA (1) ZA201606327B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3110434T3 (en) * 2014-02-24 2019-01-14 Takeda Gmbh UTI FUSION PROTEINS
US20200165632A1 (en) * 2017-06-07 2020-05-28 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
WO2021178843A1 (en) * 2020-03-05 2021-09-10 DiaMedica USA Inc. Ulinastatin polypeptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DK0401508T3 (da) 1989-05-13 1995-05-15 Bayer Ag Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
US5409895A (en) 1990-11-13 1995-04-25 Mochida Pharmaceutical Co., Ltd. Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
BR9708021A (pt) 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
RU2429245C2 (ru) * 2004-03-30 2011-09-20 Глаксо Груп Лимитед Иммуноглобулины
EP1791866A2 (en) 2004-08-11 2007-06-06 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
CN101189334B (zh) * 2005-06-03 2013-11-06 持田制药株式会社 抗cd14抗体融合蛋白质
CA2635589C (en) 2005-12-29 2017-01-17 Dyax Corp. Protease inhibition
DK2334705T3 (en) * 2008-09-26 2017-03-27 Ucb Biopharma Sprl BIOLOGICAL PRODUCTS
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
KR102428875B1 (ko) * 2011-04-29 2022-08-05 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
CA2857168C (en) * 2011-12-01 2020-10-27 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
BR112014026162A2 (pt) * 2012-04-23 2017-10-03 Nrl Pharma Inc Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
CN103044554B (zh) 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
DK3110434T3 (en) * 2014-02-24 2019-01-14 Takeda Gmbh UTI FUSION PROTEINS

Also Published As

Publication number Publication date
SG10201708400QA (en) 2017-11-29
MX2019013124A (es) 2020-08-31
SG11201606691QA (en) 2016-09-29
EA201691702A1 (ru) 2017-01-30
CA3178241A1 (en) 2015-08-27
EP3110434B1 (en) 2018-09-19
AU2021225156A1 (en) 2021-09-30
CN110092837A (zh) 2019-08-06
US10351618B2 (en) 2019-07-16
PT3110434T (pt) 2018-12-19
ECSP16076535A (es) 2017-08-31
EA037256B1 (ru) 2021-02-26
TWI694084B (zh) 2020-05-21
KR20220151005A (ko) 2022-11-11
US20160362475A1 (en) 2016-12-15
CL2016002136A1 (es) 2017-08-11
JP2023123763A (ja) 2023-09-05
AU2021225156B2 (en) 2022-11-24
PL3110434T3 (pl) 2019-01-31
NZ760789A (en) 2023-03-31
CR20160444A (es) 2017-04-21
TW201630931A (zh) 2016-09-01
IL247321B (en) 2020-06-30
PH12016501629A1 (en) 2017-02-06
KR20160141718A (ko) 2016-12-09
EP3110434A1 (en) 2017-01-04
US20200040062A1 (en) 2020-02-06
CA2939639A1 (en) 2015-08-27
CN106232135B (zh) 2019-12-10
AU2023200875A1 (en) 2023-04-27
CN110092837B (zh) 2024-01-02
JP2022002513A (ja) 2022-01-11
MY178774A (en) 2020-10-20
AU2019204448B2 (en) 2021-06-10
DOP2016000202A (es) 2016-12-15
SI3110434T1 (sl) 2019-02-28
JP6938565B2 (ja) 2021-09-22
KR102461210B1 (ko) 2022-10-31
AU2015218704A1 (en) 2016-09-22
CA2939639C (en) 2023-01-24
NZ724196A (en) 2022-01-28
JP6574431B2 (ja) 2019-09-11
AU2019204448A1 (en) 2019-07-11
EP3443978A1 (en) 2019-02-20
JO3729B1 (ar) 2021-01-31
MX2016010950A (es) 2017-04-25
US20220127334A1 (en) 2022-04-28
AU2015218704B2 (en) 2019-05-02
BR112016019390B1 (pt) 2023-11-14
NZ760008A (en) 2023-03-31
AR101597A1 (es) 2016-12-28
US20180072795A1 (en) 2018-03-15
UA118866C2 (uk) 2019-03-25
MA39347B2 (fr) 2020-05-29
EA202091567A1 (ru) 2021-07-30
LT3110434T (lt) 2018-12-27
BR112016019390A2 (pt) 2017-10-24
DK3110434T3 (en) 2019-01-14
JP2017512058A (ja) 2017-05-18
MA39347A1 (fr) 2018-06-29
HRP20182029T1 (hr) 2019-02-08
IL247321A0 (en) 2016-09-29
RS58285B1 (sr) 2019-03-29
US9856310B2 (en) 2018-01-02
ES2700149T3 (es) 2019-02-14
JP2019187427A (ja) 2019-10-31
WO2015127391A1 (en) 2015-08-27
CY1120997T1 (el) 2019-12-11
ZA201606327B (en) 2019-01-30
CN106232135A (zh) 2016-12-14
GEP20196970B (en) 2019-04-25

Similar Documents

Publication Publication Date Title
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
PE20170257A1 (es) Proteinas de fusion uti
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
MD3827845T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
MX2017006866A (es) Pares de unión para producción de péptidos.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
EA201790895A1 (ru) Модифицированные полипептиды fgf-21 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2018000042A1 (es) Anticuerpos de unión a tau
EA202092435A3 (ru) Моноклональные антитела против bcma
BR112019012343A2 (pt) anticorpos il-11ra
EA201691607A1 (ru) Микроорганоиды и способы их получения и применения
MX2016016886A (es) Anticuerpos anti-axl.
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
GEP20217252B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
CL2018000043A1 (es) Anticuerpos de unión a tau
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
EA201891573A1 (ru) Конъюгат терапевтических ферментов
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201591421A1 (ru) Препараты полипептида фактора ix
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
EA201791937A1 (ru) Противовоспалительные полипептиды